An experienced biopharmaceutical executive with a track record in leading drug development processes, leading and scaling biotech companies. Prior to Kailo Pharma, she served as the CEO at The National Institute for Biotechnology in the Negev (NIBN) Ltd, an accelerator company of diverse biotechnologies. Previously, served as COO\active-CEO at Tiltan Pharma Ltd, a clinical stage (phase II) company that developed a combination therapy for treating metastatic pancreatic cancer. Prior, she held executive leadership roles at the Global Innovative R&D unit leading innovative drug development projects and at Teva Innovative Venture (TIV) unit at Teva Pharmaceuticals Ltd. Her first leading role was at Peptor Ltd as team leader developing a peptide PKB inhibitor for treating cancer. Currently and over the years, she has been continually serving on the Board of Directors of Biotech companies.
Dr Ohne Holds a PhD in Immunology from Tel-Aviv University.
